Lincosamides
Lincosamides are antibiotics used mainly to treat G + infections. These include lincomycin and clindamycin. Older lincomycin is no longer used in practice.
Mechanism of action[edit | edit source]
Lincosamides inhibit protein synthesis by binding to the 50S subunit of the ribosome.
Antimicrobial spectrum[edit | edit source]
It acts mainly on G + bacteria such as staphylococci and streptococci. They are also effective against anaerobes, some G− rods. Clostridium difficile, Neisseria, hemophilia and others are resistant.
Pharmacokinetics[edit | edit source]
Clindamycin after administration absorbs well. Penetrates body fluids and tissues, including bones. However, the penetration into the cerebrospinal fluid is small. It is excreted by the kidneys.
Pharmacodynamics[edit | edit source]
The effect of clindamycin is independent of concentration.
Resistance[edit | edit source]
The mechanism of resistance is the modification of ribosomes.
Indication[edit | edit source]
- Β-lactam variant in patients with hypersensitivity to penicillin.
- Treatment of G + and anaerobic infections. Osteomyelitis caused by S. aureus, infections of joints and tendons. Infections insensitive to other antistaphylococcal antibiotics.
- Hospital use in patients with bone and soft tissue infections (intra-abdominal mixed aerobic anaerobic infections in combination with aminoglycosides) mainly in infections that have arisen in connection with abdominal surgery.
- Locally in acne vulgaris.
Clindamycin[edit | edit source]
Clindamycin is one of lincosamides, which are antibiotics used as an alternative in the treatment of infections caused by gram-positive and anaerobic bacteria in patients hypersensitive to penicillins or other β-lactam antibiotics.
Mechanism of action[edit | edit source]
It consists in inhibiting proteosynthesis by binding to the 50S subunit of ribosomes of susceptible bacteria.
Spectrum[edit | edit source]
- Anaerobic bacteria - Bacteroides fragilis, Actinomyces species, Propionibacterium acnes, Fusobacterium species, Clostridium perfringens
- Clostridium difficile is always resistant
- Gram-positive bacteria - Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Corynebacterium diphtheriae
- Other microorganisms - Pneumocystis carinii, Plasmodium species
Resistance[edit | edit source]
- The inability of a microorganism to take up an antibiotic (due to the increased ability of the drug to efflux from the cell).
- Decreased affinity of ribosome binding sites based on genetic modification of the 50S subunit.
- Bacterial cell esterase production.
- These enzymes subsequently break down the antibiotic molecule and thus inactivate it.
- There is cross-resistance between clindamycin and macrolides.
Pharmacokinetics[edit | edit source]
Absorption[edit | edit source]
- After oral administration, it is well absorbed even in the presence of food.
- For severe infections, it can also be given parenterally.
- It has up to 90% bioavailability.
Distribution[edit | edit source]
- Clindamycin has a relatively high volume of distribution - about 1.1 l / kg.
- Up to 93% of the absorbed dose is bound to plasma proteins.
- In sufficient concentrations, it penetrates most tissues and body fluids, including bones and abscesses.
- Penetration into the cerebrospinal fluid is not sufficient even in inflammation (which usually increases the permeability of the blood-brain barrier).
Metabolism and excretion[edit | edit source]
- It undergoes oxidative metabolism in the liver and metabolites are excreted by glomerular filtration.
- The half-life of clindamycin is approximately 3 hours, but is prolonged in patients with liver or kidney disease (dose adjustment required).
Side effects[edit | edit source]
- Rash: up to 10% of patients.
- Pseudomembranous colitis with overgrowth of Clostridium difficile - if present, vancomycin or metronidazole are given.
- Indigestion. Inhibition of neuromuscular transmission - increases the effect of muscle relaxants.
Dosing strategies[edit | edit source]
Clindamycin is one of the antibiotics with a concentration-independent effect. The goal of dosing is to maintain effective concentrations above the MIC (minimum inhibitory concentration) of susceptible microorganisms for at least 50% of the dosing interval, which is 6-8 hours.
Clinical indications[edit | edit source]
- Intra-abdominal and pelvic infections with presumed involvement of anaerobic bacteria - peritonitis, abscesses, septic abortion.
- Staphylococcal and streptococcal osteomyelitis.
- Diabetic foot infection (in combination with antibiotics effective against aerobic gram-negative sticks).
- Severe infections caused by Streptococcus pyogenes - necrotizing fasciitis, myositis, toxic shock. Severe streptococcal and staphylococcal cellulitis.
- Severe orofacial inflammation, including retropharyngeal abscess.
- Prevention of bone inflammation in dental surgery.
- Acne vulgaris - topical administration. Aerobic vaginitis caused by streptococci, staphylococci, enterococci, E.coli - topical administration (vaginal tablet or cream)
Odkazy[edit | edit source]
Links[edit | edit source]
Související články[edit | edit source]
Reference[3][edit | edit source]
- ↑
- ↑
- ↑ LINCOVÁ, Dagmar and Hassan FARGHALI, et al. Basic and applied pharmacology. 2nd edition. Prague: Galén, 2007. ISBN 978-80-7262-373-0 . ↑ a bSkočit nahoru k: MARTÍNKOVÁ, Jiřina, Stanislav MIČUDA and Jolana CERMANOVÁ, et al. Selected chapters from clinical pharmacology for bachelor study [online]. © 2005. [feeling. 2010-08-14]. < https://www.lfhk.cuni.cz/farmakol/predn/prednbak.htm/ >.
Kategorie:Farmakologie Kategorie:Mikrobiologie Kategorie:Infekční lékařství